Type I IFN drives neutrophil swarming, impeding lung T cell–macrophage interactions and TB control
Journal of Experimental Medicine · 01.12.2025 · 222 (12)
DOI: 10.1084/jem.20250466 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Experimental Medicine, online erschienen am 23.09.2025. Verfasst von William J Branchett und 11 weiteren Autor:innen. Beteiligte Einrichtung: Immunoregulation and Infection Laboratory, The Francis Crick Institute, London, UK. Hauptthemen laut MEDLINE: Interferon Type I, Neutrophils, Tuberculosis, Pulmonary, Macrophages, Alveolar. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 78 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: UK Medical Research Council, Wellcome Trust, Cancer Research UK.
Abstract (Originalsprache)
The early immune mechanisms determining Mycobacterium tuberculosis infection outcome are unclear. Using bulk and scRNA-seq over the first weeks of infection, we describe an unexpected, higher early pulmonary type I IFN response in relatively resistant C57BL/6 as compared with highly TB-susceptible C3HeB/FeJ mice. C57BL/6 mice showed pronounced early monocyte-derived macrophage (MDM) accumulation and extensive CD4+ T cell–MDM interactions in lung lesions, accompanied by high expression of T cell–attractant chemokines by MDMs. Conversely, lesions in C3HeB/FeJ mice were dominated by neutrophils with high expression of pro-inflammatory chemokines, from which CD4+ T cells were spatially segregated. Early type I IFN signaling blockade reduced bacterial load and neutrophil swarming within early TB lesions while increasing CD4+ T cell numbers in both C57BL/6 and C3HeB/FeJ mice, with later more pronounced effects on bacterial load in C3HeB/FeJ mice. These data suggest that early type I IFN signaling during M. tuberculosis infection favors neutrophil accumulation and limits CD4+ T cell infiltration into developing lesions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Immunoregulation and Infection Laboratory, The Francis Crick Institute, London, UK.
- Immunoregulation Laboratory, i3S , Porto, Portugal.
- Instituto de Ciências Biomédicas Abel Salazar, University of Porto , Porto, Portugal.
- Genomics Science Technology Platform, The Francis Crick Institute , London, UK.
- Experimental Histopathology Science Technology Platform, The Francis Crick Institute , London, UK.
- Host-Pathogen Interactions in Tuberculosis Laboratory, The Francis Crick Institute, London, UK.
ORCID-Profile: William J Branchett, Evangelos Stavropoulos, Jessica Shields, Alaa Al-Dibouni, Marcos Cardoso, Ana Isabel Fernandes, Lúcia Moreira-Teixeira, Hubert Slawinski, Anna Mikolajczak, Angela Rodgers, Margarida Saraiva, Anne O'Garra
Förderung
- UK Medical Research Council
- Wellcome Trust
- Cancer Research UK
- La Caixa Foundation
- Wellcome Investigator
- Fundação para a Ciência e a Tecnologia, Portugal
- Francis Crick Institute
Zitieren
APA
Branchett, W. J., Stavropoulos, E., Shields, J., Al-Dibouni, A., Cardoso, M., Fernandes, A. I., Moreira-Teixeira, L., Slawinski, H., Mikolajczak, A., Rodgers, A., Saraiva, M., & O'Garra, A. (2025). Type I IFN drives neutrophil swarming, impeding lung T cell–macrophage interactions and TB control. Journal of Experimental Medicine, 222(12). https://doi.org/10.1084/jem.20250466
Vancouver
Branchett WJ, Stavropoulos E, Shields J, Al-Dibouni A, Cardoso M, Fernandes AI, et al. Type I IFN drives neutrophil swarming, impeding lung T cell–macrophage interactions and TB control. Journal of Experimental Medicine. 2025;222(12). doi:10.1084/jem.20250466
BibTeX
@article{Branchett2025,
author = {Branchett, William J and Stavropoulos, Evangelos and Shields, Jessica and Al-Dibouni, Alaa and Cardoso, Marcos and Fernandes, Ana Isabel and Moreira-Teixeira, Lúcia and Slawinski, Hubert and Mikolajczak, Anna and Rodgers, Angela and Saraiva, Margarida and O'Garra, Anne},
title = {Type I IFN drives neutrophil swarming, impeding lung T cell–macrophage interactions and TB control},
journal = {Journal of Experimental Medicine},
year = {2025},
volume = {222},
number = {12},
doi = {10.1084/jem.20250466}
}
EUVIMED